Quantcast

Latest Naloxone Stories

2011-03-14 20:52:24

Researchers from Boston University School of Medicine (BUSM) have found that for the majority of patients with opioid addiction, collaborative care with nurse care managers is a successful method of service delivery while effectively utilizing the time of physicians prescribing buprenorphine. The findings, which appear in the March 14 issue of the Archives of Internal Medicine, serve as a model of service delivery for facilitating access and improving outcomes in patients with opioid...

2011-03-11 05:30:00

RALEIGH, N.C., March 11, 2011 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announces that it has received definitive commitments from institutional investors for a private placement financing yielding gross proceeds of $15 million to BDSI. The financing is expected to close today. (Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO ) Under the terms of a securities purchase agreement entered into with the investors, BDSI will sell an aggregate of...

2011-03-02 07:00:00

RALEIGH, N.C., March 2, 2011 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced the positive outcome of a pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) on the development program for BEMA Buprenorphine/Naloxone, BDSI's potential treatment for opioid dependence. The development program discussed is based on pharmacokinetic and safety data for a 505(b)(2) New Drug Application (NDA). (Logo:...

2011-02-22 09:36:00

WARREN, N.J., Feb. 22, 2011 /PRNewswire/ -- MonoSol Rx, LLC ("MonoSol Rx"), the developer of PharmFilm® drug delivery technology, today announced that Reckitt Benckiser Pharmaceuticals Inc., a wholly-owned subsidiary of Reckitt Benckiser Group plc ("the Group") (LSE: RB), provided an update on U.S. market adoption of Suboxone® (buprenorphine HCl/naloxone HCl dihydrate) sublingual film for the treatment of opioid dependence during its announcement of...

2010-10-12 18:57:12

Helping to address the issue of medication adherence, persons with opioid dependence who had the medication buprenorphine implanted had less opioid use over 16 weeks, according to a study in the October 13 issue of JAMA. Dependence on opioids, in the form of heroin or prescription pain medications, is a significant health concern. A treatment that has been increasing in usage is the medication buprenorphine, with numerous studies supporting the efficacy of sublingually (beneath the tongue)...

2010-09-15 23:00:00

BALTIMORE, Sept. 16 /PRNewswire/ -- Findings from a new national survey, sponsored by the American Pain Foundation, reveal misperceptions among physicians regarding the misuse and abuse of opioids. The results come in light of government statistics to be released today looking at the broader U.S. population, showing 2009 rates of nonmedical use of these products nationwide.(1) According to the survey of physicians, a majority (56%) believe that only a small number of their patients...

2010-09-09 12:07:00

STAMFORD, Conn., Sept. 9 /PRNewswire/ -- Purdue Pharma L.P. will present data from the clinical program for Butrans(TM) (buprenorphine) Transdermal System CIII in a series of posters at PAINWeek® 2010, September 8-10 in Las Vegas. Butrans recently received marketing approval from the U.S. Food and Drug Administration and is expected to be commercially available in the U. S. during the first quarter of 2011. The featured studies evaluated the safety and efficacy of...

2010-08-31 08:30:00

WARREN, N.J., Aug. 31 /PRNewswire/ -- MonoSol Rx, the developers of PharmFilm® technology and a drug delivery company specializing in film pharmaceutical products, today announced that its partner, Reckitt Benckiser Pharmaceuticals Inc., a wholly-owned subsidiary of Reckitt Benckiser Group plc (LSE: RB), has received approval from the U.S. Food and Drug Administration (FDA) to market Suboxone® (buprenorphine HCl/naloxone HCl dihydrate) sublingual film...

2010-03-30 17:00:00

SOUTH SAN FRANCISCO, Calif., March 30 /PRNewswire-FirstCall/ -- Titan Pharmaceuticals, Inc. (Pink Sheets: TTNP) today announced the initiation of a randomized, placebo and active controlled, multi-center Phase 3 clinical study of Probuphine in the treatment of opioid addiction. This confirmatory Phase 3 study will be conducted at approximately 23 sites in the United States and randomize approximately 250 patients into three arms: Probuphine (100 patients), Suboxone® (100...

2009-10-27 11:35:00

SAN DIEGO, Oct. 27 /PRNewswire-FirstCall/ -- Data from a phase II study demonstrated that oral NKTR-118 improved lower gastrointestinal dysfunction by increasing the frequency of bowel movements in patients with opioid-induced constipation, while simultaneously preserving opioid-mediated analgesia. NKTR-118, an oral peripherally-acting opioid antagonist, is an investigational product candidate in clinical development for the treatment of opioid-induced constipation. (Logo:...


Word of the Day
cruet
  • A vial or small glass bottle, especially one for holding vinegar, oil, etc.; a caster for liquids.
This word is Middle English in origin, and ultimately comes from the Old French, diminutive of 'crue,' flask.
Related